Vaccines Archives

News and Trends 17 Jul 2015

GSK and Partners Bavarian Nordic and J&J Ebola vaccine candidates both reach Phase II

In outbreak situations such as the Ebola crisis, vaccines play an essential role that was largely needed during the 2014 health emergency, especially when the plague reached the First World. To ensure preparedness against Ebola, now and in the future, companies have been rushing to develop vaccines against this disease. GSK has come up with […]

July 17, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 30 Jun 2015

Oldest French Biotech Transgene is One Step Closer to Bankruptcy

Transgene, the oldest French Biotech company announced just yesterday that it will cut 120 jobs on its current 300 employees. The company will shut down its manufacturing facility in order to focus on the Research and Development of its therapeutic vaccine candidates. Wise move or final last words? Back in 1976, Robert Swanson and Herbert Boyer founded […]

June 30, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 29 Jun 2015

Actelion & the Max Planck Society created the new leader in Synthetic Carbohydrate Vaccines

Actelion has created a new start-up in the field of synthetic carbohydrate vaccines, together with the Max Planck Society. Actelion has made a funding commitment of up to €30M to back the new company, Vaxxilon. Prof. Dr. Peter Seeberger and his team at the Max Planck Institute of Colloids and Interfaces discovered the first preclinical […]

June 29, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 25 Jun 2015

BioNTech and Siemens to build a new Production plant for Personalized Cancer Vaccines

Personalized medicine is the next thing and immunotherapy expert BioNTech is determined to build its place in this competitive field. With this purpose in mind, the German biotech will partner with Siemens to build a new production plant for personalized cancer vaccines. Founded in 2008, the BioNTech Group has become one of the fastest-growing biotechnology […]

June 25, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 25 May 2015

Invectys focuses on Telomers to develop a Universal Cancer Vaccine

French startup Invectys believes to have found the solution to cancer: one vaccine to cure them all! By targeting telomerase, this new immunotherapy could theoretically fight 95 % of all human cancers. When a cell divides, a small piece of DNA, called telomere, is lost at both ends of each chromosome. Telomerase adds these pieces of DNA again at the end of […]

May 25, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 13 May 2015

Sanofi and Selecta will develop a “Negative Vaccine” for Celiac Disease

Sanofi and Selecta Biosciences are going to extend their three-year-old partnership to develop an immunotherapy for the treatment of celiac disease. Selecta may receive €264M from the biggest French Pharma company, in terms of research support and sales milestones. The two companies are now collaborating on three programs for immune tolerance. In celiac disease patients, […]

May 13, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 22 Apr 2015

Vaccines against Parasites, on the Horizon with XstalBio

XstalBio has commenced work on an €9.3M EU Funded Horizon 2020 project to develop vaccines that protect cattle, sheep and poultry, against infection by parasites. The 4 year “PARAGONE” collaboration involves 17 partners from Europe, Uruguay and China and will aim to move several candidate vaccines from the laboratory into practical field trials. XstalBio, as […]

April 22, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Apr 2015

The challenge of terminal sterilization of Proteins

The production of biologicals is an important challenge for the industry. Today, very often, the only way to have a sterile final product is to, first, use sterile components and then, launch the production in a fully aseptic manufacturing facility. What if we could terminally sterilize the protein-based outcome once produced? More and more biologicals are brought to the market, […]

April 16, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 23 Mar 2015

A Vaccine against Placental Malaria made with ExpreS2ion’s Protein Expression Technology

University of Copenhagen released a vaccine candidate against the form of malaria that strikes pregnant women, for testing in humans. The vaccine candidate contains a malaria antigen made with ExpreS2ion Biotechnologies’ protein expression technology, ExpreS2. This vaccine candidate results from many years of research done by Professor Ali Salanti and his team at the Department […]

March 23, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 22 Feb 2015

Theravectys: an Orphan Drug Designation for Its Lentiviral Vector-Based Therapeutic Vaccine

THERAVECTYS, a fully-integrated discovery and clinical development biotechnology company focusing on the development of therapeutic vaccines and immunotherapy, announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to its therapeutic vaccine candidate for the treatment of Adult T-cell Leukemia/Lymphoma (ATL/L). ATL/L is a rare malignancy of a certain type of white cells, T-Lymphocytes, caused by the Human T-Cell Lymphotropic Virus type […]

February 22, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 14 Feb 2015

GlycoVaxyn: A new Gain for GSK’s Vaccines Business

GSK, who was already a minority shareholder in GlycoVaxyn, acquires the company and its biological conjugation platform which may help it to develop a new generation of prophylactic vaccines against bacterial infections. GSK has today paid €167M to purchase the remaining stake in the company. GlycoVaxyn’s innovative biological conjugation platform originates enables the development of […]

February 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 31 Jan 2015

An Anglo-French Partnership To Cure Hepatitis B

European biotechnology company Valneva and UK company Immune Targeting Systems (ITS) announced that they have signed an exclusive worldwide commercial license agreement. This deal grants ITS the rights to research, develop and commercialize Hepatitis B vaccine candidates in combination with Valneva’s IC31 Adjuvant. Valneva’s IC31 Adjuvant is a unique synthetic adjuvant combining the immuno-stimulating properties […]

January 31, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Vaccines

GSK and Partners Bavarian Nordic and J&J Ebola vaccine candidates both reach Phase II

Oldest French Biotech Transgene is One Step Closer to Bankruptcy

Actelion & the Max Planck Society created the new leader in Synthetic Carbohydrate Vaccines

BioNTech and Siemens to build a new Production plant for Personalized Cancer Vaccines

Invectys focuses on Telomers to develop a Universal Cancer Vaccine

Sanofi and Selecta will develop a “Negative Vaccine” for Celiac Disease

Vaccines against Parasites, on the Horizon with XstalBio

The challenge of terminal sterilization of Proteins

A Vaccine against Placental Malaria made with ExpreS2ion’s Protein Expression Technology

Theravectys: an Orphan Drug Designation for Its Lentiviral Vector-Based Therapeutic Vaccine

GlycoVaxyn: A new Gain for GSK’s Vaccines Business

An Anglo-French Partnership To Cure Hepatitis B

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!